SCHEMBL4648440

SCHEMBL4648440

FC(F)(F)C(F)(F)C(OC(C(F)(F)F)(C(F)(F)F)C(F)(F)C(F)(F)F)(C(F)(F)F)C(F)(F)F

nearest known ligand 0.30

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL458635 0.79
SCHEMBL31326556 0.76 LMNA (0.39) LMNA
SCHEMBL30984481 0.74
SCHEMBL11239609 0.74
SCHEMBL9588072 0.74 LMNA (0.30) LMNA
SCHEMBL9588957 0.74 LMNA (0.30) LMNA
SCHEMBL11032982 0.74 LMNA (0.36) LMNA
SCHEMBL9588287 0.74 LMNA (0.30) LMNA
SCHEMBL23835547 0.73
SCHEMBL30984477 0.72 LMNA (0.32) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0988061-A4 METHODS FOR DELIVERING BIOACTIVE AGENTS IMARX PHARMACEUTICAL CORP (US) 2002-05-02 EP claimed
US-6143276-A ADMINISTERING TO THE PATIENT A COMPOSITION COMPRISING A BIOACTIVE AGENT AND A GASEOUS PRECURSOR CAPABLE OF UNDERGOING PHASE TRANSITION TO A GAS AT A REGION OF ELEVATED TEMPERATURE IN THE PATIENT IMARX PHARMACEUTICAL CORP. (US) 2000-11-07 US claimed
EP-0988061-A1 METHODS FOR DELIVERING BIOACTIVE AGENTS IMARX PHARMACEUTICAL CORP. (US) 2000-03-29 EP claimed
WO-1998042384-A1 METHODS FOR DELIVERING BIOACTIVE AGENTS IMARX PHARMACEUTICAL CORP. (US) 1998-10-01 WO claimed
EP-2766001-B1 BUFFERED OXYGEN THERAPEUTIC NUVOX PHARMA LLC (US) 2024-05-15 EP disclosed
CN-108685882-A The oxygen therapy agent of buffering 努沃克斯制药有限责任公司 2018-10-23 CN disclosed
CN-104039317-B Buffered oxygen therapeutics 努沃克斯制药有限责任公司 2018-05-25 CN disclosed
US-20170071193-A1 FLUID FOR SUSPENDED ANIMATION NUVOX PHARMA LLC (US) 2017-03-16 US disclosed
CN-104039317-A Buffered oxygen therapeutics NUVOX PHARMA L L C 2014-09-10 CN disclosed
US-8822549-B2 Buffered oxygen therapeutic NUVOX PHARMA LLC 2014-09-02 US disclosed
EP-2766001-A1 BUFFERED OXYGEN THERAPEUTIC Nuvox Pharma, LLC (US) 2014-08-20 EP disclosed
US-20130330706-A1 Fluid for Suspended Animation NUVOX PHARMA, L.L.C. 2013-12-12 US disclosed
WO-1999030620-A1 OPTOACOUSTIC CONTRAST AGENTS AND METHODS FOR THEIR USE IMARX PHARMACEUTICAL CORP. (US) 1999-06-24 WO disclosed
EP-0901793-A1 Thermal preactivation of gaseous precursor filled compositions IMARX PHARMACEUTICAL CORP. (US) 1999-03-17 EP disclosed
US-5864968-A Shoe with perfluoropolyether insole MANN MORRIS A (US) 1999-02-02 US disclosed
WO-1998057670-A1 OXYGEN DELIVERY AGENTS AND USES FOR THE SAME IMARX PHARMACEUTICAL CORP. (US) 1998-12-23 WO disclosed
WO-1998050041-A1 NOVEL PRODRUGS COMPRISING FLUORINATED AMPHIPHILES IMARX PHARMACEUTICAL CORP. (US) 1998-11-12 WO disclosed
WO-1998042383-A1 CHARGED LIPIDS AND USES FOR THE SAME IMARX PHARMACEUTICAL CORP. (US) 1998-10-01 WO disclosed
WO-1998042384-A1 METHODS FOR DELIVERING BIOACTIVE AGENTS IMARX PHARMACEUTICAL CORP. (US) 1998-10-01 WO disclosed
US-5705179-A Tissue augmentation with perfluoropolyether compounds VIVANTE INTERNATINALE, INC. (US) 1998-01-06 US disclosed